GlassScriptPhysician profile
Stephen A Bookbinder
NPI 1699767202
$6,512.53
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,882 · 2020: $1,627 · 2021: $1,450 · 2022: $1,554.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,348.47 | 2019-2022 | |
| Amgen INC. | $1,064.14 | 2019-2022 | |
| Janssen Biotech, INC. | $661.48 | 2020-2022 | |
| Ucb, INC. | $650.38 | 2019-2022 | |
| Horizon Therapeutics Plc | $444.48 | 2019-2022 | |
| Pfizer INC. | $427.70 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $391.61 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $350.81 | 2019-2022 | |
| Genzyme Corporation | $242.08 | 2019-2020 | |
| Genentech USA, INC. | $163.96 | 2019-2020 | |
| Glaxosmithkline, LLC. | $155.60 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.76 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $112.21 | 2022 | |
| Radius Health, INC. | $78.71 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $70.28 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $65.26 | 2019-2020 | |
| Lilly USA, LLC | $54.27 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $49.30 | 2019 | |
| Bioventus LLC | $27.78 | 2019-2021 | |
| Tersera Therapeutics LLC | $16.57 | 2021 | |
| Eisai INC. | $12.15 | 2020 | |
| Organon LLC | $7.53 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bookbinder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.